Product Name:
Btk-pY551
Product Number:
ab-pk551
Target Full Name: Bruton's agammaglobulinemia tyrosine kinase
Target Alias: Agammaglobulinaemia tyrosine kinase; AGMX1; ATK; B cell progenitor kinase; BPK; Bruton agammaglobulinemia tyrosine kinase; EMB; IMD1; XLA; AT; ATK; BPK; XLA; IMD1; AGMX1; PSCTK1; MGC126261; MGC126262; RP1-164F3_2; XLA; ENSG00000010671
Product Type Specific: Btk protein kinase phosphosite-specific antibody
Antibody Code: PK551
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: Y551
Protein UniProt: Q06187
Protein SigNET: Btk
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human Btk sequence peptide Cat. No.: PE-04AIX90
Antibody Immunogen Sequence: DDE(pY)TSS(bA)C
Antibody Immunogen Description: Corresponds to amino acid residues D548 to S554; in the protein kinase catalytic domain.Y551 phosphorylation stimulates phosphotransferase activity, and regulates intracellular location and molecular association, including inducing interaction with BLNK. This is one of the major in vivo phosphorylation sites in Btk (≥148 reports from high throughput mass spectrometry studies recorded in PhosphoSitePlus). Btk is known to be phosphorylated at this site in vitro by Btk, Lyn, PIK3CD, Src, Syk.
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 0.5 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Medium immunoreactivity of a target-sized protein by Western blotting in Jurkat and HEK-293 cells. Medium immunoreactivity with immunogen peptide on dot blots.
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Chimpanzee | Dog | Mouse | Platypus | Chicken | Zebra fish | Fruit fly.
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 75-80 kDa.
Antibody Specificity: High
Antibody Cross Reactivity: Two cross-reactive proteins of ~120 and 140 kDa are detected in HEK-293 cells.
Related Product 1: Btk (548-554) pY551 antibody blocking peptide (Cat. No.: PE-04AIX90)
Related Product 2: Btk Y223+Y225 phosphorylation antibody (Cat. No.: AB-PK550)
Scientific Background: BTK is a protein-tyrosine kinase of the TK group and Tec family. It is a non-receptor kinase that is essential for B-cell development, differentiation, and function. In addition, BTK phosphotransferase activity is required for radiation induced apoptosis in immune cells. After B-cell receptor (BCR) activation, BTK translocates to the plasma membrane and is phosphorylated on Tyr-551 catalyzed by the Lyn and Syk proteins, followed by autophosphorylation at Tyr-223. Phosphorylation at Tyr-223 and Tyr-551 increases phosphotransferase activity.Phosphorylation at Ser-180 causes translocation back to the cytoplasm, leading to downstream phosphorylation of PLCG2 at several conserved phosphosites and the stimulation of downstream calcium dependent signalling mechanisms. It consists of several domains, including a PH domain (crucial for membrane localization), SH2 and SH3 domains (protein-protein interactions), and a kinase domain. BTK acts as a scaffold to bring together various intracellular signalling proteins to function in cytokine receptor signalling pathways. In immune cells, It is expressed in B-cells, macrophages, neutrophils, and mast cells, but not in T-cells. It is a vital component of the toll-like receptor (TLR) pathway, which is the primary system used to identify pathogens and activate host defence systems. Due to its role in immune cell activation, BTK is a therapeutic target for diseases like rheumatoid arthritis, lupus, and chronic lymphocytic leukemia (CLL). Ibrutinib inhibits BTK and induces leukemia cells to stop growing and die. Mutations in the BTK gene cause X-linked agammaglobulinemia (XLA), a severe antibody deficiency disease. This description may include information annotated by UniProt and/or Google AI.